LGD-4033 and Testosterone Interaction

Monitor
Researched 90% confidence

LGD-4033 and Testosterone have an interaction requiring monitoring for interaction with 90% confidence. LGD-4033 causes dose-dependent suppression of endogenous testosterone through HPG axis negative feedback. Some users run a low-dose testosterone base (e.g., 100-150 mg/week TRT) alongside LGD-4033 to prevent suppression-related side effects such as low libido, lethargy, fatigue, and mood disturbance. If combining, monitor total testosterone, free testosterone, estradiol, and SHBG levels. Adding exogenous testosterone converts this from a SARM-only cycle to a testosterone cycle with regulatory and health implications. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Testosterone

Anabolic-Androgenic Steroid | Primary Male Sex Hormone

Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function.

Half-life: ~8 days (cypionate) Typical dose: 100-200 mg/week (TRT) anabolic, sexual health, metabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgeniccarcinogenic riskestrogenichematocrit raising
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate
Pancreas
low

Shared Safety Flags

2x 2 androgenic compounds (LGD-4033, Testosterone). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (LGD-4033, Testosterone). Monitor accordingly.
2x 2 estrogenic compounds (LGD-4033, Testosterone). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 hepatotoxic compounds (LGD-4033, Testosterone). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (LGD-4033, Testosterone). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (LGD-4033, Testosterone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Testosterone). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Testosterone?

Yes, but with caution. LGD-4033 causes dose-dependent suppression of endogenous testosterone through HPG axis negative feedback. Some users run a low-dose testosterone base (e.g., 100-150 mg/week TRT) alongside LGD-4033 to prevent suppression-related side effects such as low libido, lethargy, fatigue, and mood disturbance. If combining, monitor total testosterone, free testosterone, estradiol, and SHBG levels. Adding exogenous testosterone converts this from a SARM-only cycle to a testosterone cycle with regulatory and health implications. Regular monitoring is advised.

Is LGD-4033 and Testosterone safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: androgenic, carcinogenic risk, estrogenic, hepatotoxic, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between LGD-4033 and Testosterone?

LGD-4033 causes dose-dependent suppression of endogenous testosterone through HPG axis negative feedback. Some users run a low-dose testosterone base (e.g., 100-150 mg/week TRT) alongside LGD-4033 to prevent suppression-related side effects such as low libido, lethargy, fatigue, and mood disturbance. If combining, monitor total testosterone, free testosterone, estradiol, and SHBG levels. Adding exogenous testosterone converts this from a SARM-only cycle to a testosterone cycle with regulatory and health implications. This assessment has 90% confidence and is based on documented research data.

How should I time LGD-4033 and Testosterone?

LGD-4033 has a half-life of ~24-36 hours and Testosterone has a half-life of ~8 days (cypionate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Testosterone

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.